Literature DB >> 11851930

Catheter thrombosis.

G A Beathard1.   

Abstract

Catheter malfunction due to poor flow is a common problem. When it occurs early, the cause is generally technical. Late occurrences are most often related to thrombus formation. Several types of thrombus may be seen, differing by location and supposed mechanism of formation. The most common offender, however, is the fibrin sheath thrombus. Prevention of catheter malfunction is an endeavor that continues to beg many questions. Catheter malfunction should be treated early to avoid inadequate dialysis. In the past, urokinase was a highly valuable aid to the nephrologist in managing this problem. Since this agent became unavailable a suitable alternative has not emerged. Recombinant tissue plasminogen activator (tPA) seems to be the most likely candidate for this role; however, it is not currently available in a packaging form that is optimal for this purpose. Currently, catheter exchange appears to be the best available alternative for this problem, which cannot yet be resolved by simpler means.

Entities:  

Mesh:

Year:  2001        PMID: 11851930     DOI: 10.1046/j.1525-139x.2001.00109.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  7 in total

1.  Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial.

Authors:  Trevor J Wilkieson; Alistair J Ingram; Mark A Crowther; Steven D Soroka; Ryuta Nagai; Kailash K Jindal; Catherine M Clase
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

2.  Improved Hemocompatibility of Multilumen Catheters via Nitric Oxide (NO) Release from S-Nitroso-N-acetylpenicillamine (SNAP) Composite Filled Lumen.

Authors:  Elizabeth J Brisbois; Maria Kim; Xuewei Wang; Azmath Mohammed; Terry C Major; Jianfeng Wu; Jessica Brownstein; Chuanwu Xi; Hitesh Handa; Robert H Bartlett; Mark E Meyerhoff
Journal:  ACS Appl Mater Interfaces       Date:  2016-10-21       Impact factor: 9.229

Review 3.  Standardized definitions for hemodialysis vascular access.

Authors:  Timmy Lee; Michele Mokrzycki; Louise Moist; Ivan Maya; Miguel Vazquez; Charmaine E Lok
Journal:  Semin Dial       Date:  2011-09-09       Impact factor: 3.455

Review 4.  Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease.

Authors:  Ying Wang; Jessica N Ivany; Vlado Perkovic; Martin P Gallagher; Mark Woodward; Meg J Jardine
Journal:  Cochrane Database Syst Rev       Date:  2016-04-04

5.  Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model.

Authors:  Otmar R Buyne; Robert P Bleichrodt; Harry van Goor; Paul E Verweij; Thijs Hendriks
Journal:  Int J Colorectal Dis       Date:  2006-11-07       Impact factor: 2.796

6.  An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.

Authors:  Peter C Thomson; Patrick B Mark; Michele Robertson; Claire White; Stefan D Anker; Sunil Bhandari; Kenneth Farrington; Alan G Jardine; Philip A Kalra; John McMurray; Donal Reddan; David C Wheeler; Christopher G Winearls; Ian Ford; Iain C Macdougall
Journal:  Kidney Int Rep       Date:  2022-05-18

7.  Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.

Authors:  Dominika Wójtowicz; Dominika Cholewa; Anna M Faba; Beata Domańska; Joanna Kokoszka; Konrad Kopacz; Rafał Ficek; Tomasz Irzyniec; Sylwia E Rotkegel; Jerzy Chudek
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.